What smart money is saying about Roivant Sciences
1 fund in our archive has pitched Roivant Sciences — most recently Baron Health Care Fund in September 2025.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Get an email when a fund writes about it
Position history
Between Q3 2025 and Q2 2026, 1 fund letter reported a position in Roivant Sciences, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsBaron Health Care FundJune 2026
Listed in Baron Health Care Fund’s reported holdings.
Read the letterRoivant Sciences
Fund coverage · 1 thesis
- Baron Health Care FundSeptember 2025
Roivant Sciences Ltd. is a biotechnology company that develops focused subsidiaries called "Vants" to create pipeline drugs, with promising prospects for significant upside based on recent successes and ongoing projects.
Read the full thesis
Read every full thesis on Roivant Sciences
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→